Cytek Biosciences, Inc.

NasdaqGS CTKB

Cytek Biosciences, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -5.92%

Cytek Biosciences, Inc. EBT Margin is -5.92% for the Trailing 12 Months (TTM) ending September 30, 2024, a 30.98% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.
  • Cytek Biosciences, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -8.58%, a -452.48% change year over year.
  • Cytek Biosciences, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -1.55%, a -113.59% change year over year.
  • Cytek Biosciences, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was 11.42%.
Key data
Date EBT Margin Net Income Margin EBITDA Margin EBIT Margin
Market news
Loading...
SV Wall Street
NasdaqGS: CTKB

Cytek Biosciences, Inc.

CEO Dr. Wenbin Jiang Ph.D.
IPO Date July 23, 2021
Location United States
Headquarters 47215 Lakeview Boulevard
Employees 645
Sector Healthcare
Industries
Description

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated plate loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Similar companies

INGN

Inogen, Inc.

USD 11.47

-1.88%

OFIX

Orthofix Medical Inc.

USD 18.20

-0.71%

NPCE

NeuroPace, Inc.

USD 13.61

-1.09%

SSKN

STRATA Skin Sciences, Inc.

USD 2.83

4.04%

SGHT

Sight Sciences, Inc.

USD 2.73

-2.50%

AXGN

AxoGen, Inc.

USD 17.92

-1.59%

SRDX

Surmodics, Inc.

USD 34.07

0.09%

LIVN

LivaNova PLC

USD 49.95

-1.36%

ELMD

Electromed, Inc.

USD 33.88

-1.51%

APYX

Apyx Medical Corporation

USD 1.42

-1.39%

KIDS

OrthoPediatrics Corp.

USD 24.05

0.21%

RXST

RxSight, Inc.

USD 33.70

-0.50%

TMCI

Treace Medical Concepts, Inc.

USD 9.69

-3.58%

LUNG

Pulmonx Corporation

USD 5.84

2.82%

StockViz Staff

February 4, 2025

Any question? Send us an email